Browse
You are looking at 61 - 70 of 762 items for
Search for other papers by Jean-Charles Martin in
Google Scholar
PubMed
Search for other papers by Thierry Pourcher in
Google Scholar
PubMed
Search for other papers by Guillaume Phan in
Google Scholar
PubMed
Search for other papers by Julien Guglielmi in
Google Scholar
PubMed
Search for other papers by Caroline Crambes in
Google Scholar
PubMed
Search for other papers by François Caire-Maurisier in
Google Scholar
PubMed
Search for other papers by Dalila Lebsir in
Google Scholar
PubMed
Search for other papers by David Cohen in
Google Scholar
PubMed
Search for other papers by Clément Rosique in
Google Scholar
PubMed
Search for other papers by Lun Jing in
Google Scholar
PubMed
Search for other papers by Maha Hichri in
Google Scholar
PubMed
Search for other papers by Lisa Salleron in
Google Scholar
PubMed
Search for other papers by Jacques Darcourt in
Google Scholar
PubMed
Search for other papers by Maamar Souidi in
Google Scholar
PubMed
Search for other papers by Marc Benderitter in
Google Scholar
PubMed
Background
Intake of potassium iodide (KI) reduces the accumulation of radioactive iodine in the thyroid gland in the event of possible contamination by radioactive iodine released from a nuclear facility. The World Health Organization (WHO) has stated the need for research for optimal timing, appropriate dosing regimen, and safety for repetitive iodine thyroid blocking (ITB). The French PRIODAC project, addressed all these issues, involving prolonged or repeated releases of radioactive iodine. Preclinical studies established an effective dose through pharmacokinetic modeling, demonstrating the safety of repetitive KI treatment without toxicity.
Summary
Recent preclinical studies have determined an optimal effective dose for repetitive administration, associated with pharmacokinetic modeling. The results show the safety and absence of toxicity of repetitive treatment with KI. Good laboratory practice level preclinical studies corresponding to individuals >12 years have shown a safety margin established between animal doses without toxic effect. After approval from the French health authorities, the market authorization of the two tablets of KI, 65 mg/day, was defined with a new dosing scheme of a daily repetitive intake of the treatment up to 7 days unless otherwise instructed by the competent authorities for all categories of population except pregnant women and children under the age of 12 years.
Conclusion
This new marketed authorization resulting from scientific-based evidence obtained as part of the PRIODAC project may serve as an example to further harmonize the application of KI for repetitive ITB in situations of prolonged radioactive release at the European and international levels, under the umbrella of the WHO.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Camilla Bøgelund Larsen in
Google Scholar
PubMed
Search for other papers by Kristian Hillert Winther in
Google Scholar
PubMed
Search for other papers by Per Karkov Cramon in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Institute of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Nils Jakob Knudsen in
Google Scholar
PubMed
QualityMetric Inc, Johnston, Lincoln, Rhode Island, USA
Search for other papers by Jakob Bue Bjorner in
Google Scholar
PubMed
Search for other papers by Lutz Schomburg in
Google Scholar
PubMed
Search for other papers by Kamil Demircan in
Google Scholar
PubMed
Search for other papers by Thilo Samson Chillon in
Google Scholar
PubMed
Search for other papers by Jeppe Gram in
Google Scholar
PubMed
Search for other papers by Stinus Gadegaard Hansen in
Google Scholar
PubMed
Internal Medicine Research Unit, University Hospital of Southern Jutland, Aabenraa, Denmark
Search for other papers by Frans Brandt in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Institute of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Torquil Watt in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
Purpose
We investigated whether selenium supplementation improves quality-of-life (QoL) in patients with autoimmune thyroiditis (ID:NCT02013479).
Methods
We included 412 patients ≥18 years with serum thyroid peroxidase antibody (TPOAb) level ≥100 IU/mL in a multicentre double-blinded randomised clinical trial. The patients were allocated 1:1 to daily supplementation with either 200 μg selenium as selenium-enriched yeast or matching placebo tablets for 12 months, as add-on to levothyroxine (LT4) treatment. QoL, assessed by the Thyroid-related Patient-Reported-Outcome questionnaire (ThyPRO-39), was measured at baseline, after 6 weeks, and after 3, 6, 12, and 18 months.
Results
In total, 332 patients (81%) completed the intervention period, of whom 82% were women. Although QoL improved during the trial, no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention. In addition, employing linear mixed model regression no difference between the two groups was observed in the ThyPRO-39 composite score (28.8 (95% CI: 24.5–33.6) and 28.0 (24.5–33.1), respectively; P = 0.602). Stratifying the patients according to duration of the disease at inclusion, ThyPRO-39 composite score, TPOAb level, or selenium status at baseline did not significantly change the results. TPOAb levels after 12 months of intervention were lower in the selenium group than in the placebo group (1995 (95% CI: 1512–2512) vs 2344 kIU/L (1862–2951); P = 0.016) but did not influence LT4 dosage or free triiodothyronine–free thyroxine ratio.
Conclusion
In hypothyroid patients on LT4 therapy due to autoimmune thyroiditis, daily supplementation with 200 μg selenium or placebo for 12 months improved QoL to the same extent.
Search for other papers by Rui Guo in
Google Scholar
PubMed
Search for other papers by Bowen Zheng in
Google Scholar
PubMed
Search for other papers by Tao Wu in
Google Scholar
PubMed
Search for other papers by Yufan Lian in
Google Scholar
PubMed
Search for other papers by Tinghui Yin in
Google Scholar
PubMed
Search for other papers by Yuting He in
Google Scholar
PubMed
Search for other papers by Jingya Qin in
Google Scholar
PubMed
Search for other papers by Zhicheng Yao in
Google Scholar
PubMed
Search for other papers by Wen Xu in
Google Scholar
PubMed
Search for other papers by Jie Ren in
Google Scholar
PubMed
Objective
Few studies use all nodule burdens to specify the prognosis of multinodular goiter (MNG) following radiofrequency ablation (RFA), so this study addresses this question for MNG after completely ablating dominant nodules.
Methods
The RFA indications for MNG include 2–5 benign nodules with over 50% normal tissue on ultrasound, 1–3 well-defined benign dominant nodules on cytology, largest diameter ≥20 mm and/or with clinical complaints, and patient refusal or unable to undergo surgery. A retrospective study of 185 MNG patients with completely ablated dominant nodules in a single-session RFA was conducted. The efficacy and complications were evaluated at 1, 6, 12 months, and yearly thereafter. Based on retreatment risks, progressive disease (PD), stable disease (SD), and complete relief (CR) were introduced to assess all nodule load changes. PD was clarified as having new/non-target nodules that newly appeared to ACR TI-RADS≥4, or new/enlarged non-target nodules ≥1 cm.
Results
The initial ablation ratios of target nodules were 100% at one month. During a mean 22.38 ± 13.75 months (range, 12–60 months), the volume reduction rate of ablated nodules was 98.25% at 24 months without regrowth. Cosmetic and symptomatic scores decreased to 1 and 0, respectively, after 48 months. Of the patients, 9.7% (18/185) had PD and the retreatment rate was 2.2% (4/185). The complication rate was 2.7% (5/185).
Conclusion
RFA provides cosmetic and symptomatic relief for an average of two years. RFA is a useful minimally invasive treatment modality for selected MNG patients.
Search for other papers by Hsu-Hua Tseng in
Google Scholar
PubMed
Search for other papers by Yen-Bo Lin in
Google Scholar
PubMed
Search for other papers by Kuan-Yu Lin in
Google Scholar
PubMed
Search for other papers by Chia-Hung Lin in
Google Scholar
PubMed
Search for other papers by Hung-Yuan Li in
Google Scholar
PubMed
Search for other papers by Chia-Hsuin Chang in
Google Scholar
PubMed
Search for other papers by Yi-Ching Tung in
Google Scholar
PubMed
Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan
Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan
Search for other papers by Pei-Lung Chen in
Google Scholar
PubMed
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Search for other papers by Chih-Yuan Wang in
Google Scholar
PubMed
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Search for other papers by Wei-Shiung Yang in
Google Scholar
PubMed
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan
Search for other papers by Shyang-Rong Shih in
Google Scholar
PubMed
Purpose
Autoimmune polyendocrine syndrome (APS) is a rare immune-endocrinopathy characterized by the failure of at least two endocrine organs. Clinical characteristics have mainly been described in the Western population. This study comprehensively analyzed the demographic and clinical manifestations of APS II and APS III in Taiwan.
Methods
Patients aged ≥20 years with a diagnosis of APS II or APS III in ten hospitals between 2001 and 2021 were enrolled. The clinical and serological characteristics of the patients were retrospectively reviewed.
Results
Among the 187 enrolled patients (45 men and 142 women); only seven (3.7%) had APS II, while the others had APS III. Fifty-five patients developed hyperthyroidism and 44 patients developed hypothyroidism. Men were diagnosed with APS at a younger age than women (16.8 vs 27.8 years old, P = 0.007). Most patients were initially diagnosed with type 1 diabetes mellitus. There was a positive correlation between age at diagnosis and the likelihood of developing thyroid dysfunction. For every year older patients were diagnosed with APS III, the risk of developing hyperthyroidism increased by 3.6% (P = 0.002), and the risk of developing hypothyroidism increased by 3.7% (P = 0.035). Positive anti-parietal cell antibodies (APCA) were associated with a higher risk of anemia in patients with APS III (P < 0.001).
Conclusion
This study provides the most comprehensive analysis of APS II and APS III in Asia. The percentage of patients with APS II was significantly lower than in the Western population. A second autoimmune endocrinopathy may develop several years after the first one. APCA examination is valuable when evaluating anemia in patients with APS.
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Alexandra Stephenson in
Google Scholar
PubMed
Search for other papers by Shideh Mirhadi in
Google Scholar
PubMed
Search for other papers by Konrad Patyra in
Google Scholar
PubMed
Search for other papers by Michael F Moran in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Department of Pediatrics, Turku University Hospital, Turku, Finland
Search for other papers by Jukka Kero in
Google Scholar
PubMed
Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Department of Medicine, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Objective
Nonautoimmune hyperthyroidism (NAH) is rare and occurs due to a constitutively activating thyroid stimulating hormone receptor (TSHR) mutation. In contrast to other thyroid nodules, no further evaluation for malignancy is recommended for hot thyroid nodules. In the first model for NAH in mice nearly all homozygous mice had developed papillary thyroid cancer by 12 months of age.
Methods
To further evaluate these mice, whole exome sequencing and phosphoproteome analysis were employed in a further generation of mice to identify any other mutations potentially responsible and to identify the pathways involved in thyroid carcinoma development.
Results
Only three genes (Nrg1, Rrs1, Rasal2) were mutated in all mice examined, none of which were known primary drivers of papillary thyroid cancer development. Wild-type and homozygous TSHR D633H knockin mice showed distinct phosphoproteome profiles with an enrichment of altered phosphosites found in ERK/mitogen-activated protein kinase (MAPK) signaling. Most importantly, phosphosites with known downstream effects included BRAF p.S766, which forms an inhibitory site: a decrease of phosphorylation at this site suggests an increase in MEK/ERK pathway activation. The decreased phosphorylation at BRAF p.S766 would suggest decreased AMP-activated protein kinase (AMPK) signaling, which is supported by the decreased phosphorylation of STIM1 p.S257, a downstream AMPK target.
Conclusion
The modified phosphoproteome profile of the homozygous mice in combination with human literature suggests a potential signaling pathway from constitutive TSHR signaling and cAMP activation to the activation of ERK/MAPK signaling. This is the first time that a specific mechanism has been identified for a possible involvement of TSH signaling in thyroid carcinoma development.
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Nunzia Tacelli in
Google Scholar
PubMed
Search for other papers by Lucia Russo in
Google Scholar
PubMed
Search for other papers by Laetitia Lebrun in
Google Scholar
PubMed
Search for other papers by Isabelle Salmon in
Google Scholar
PubMed
Search for other papers by Gilles Russ in
Google Scholar
PubMed
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Objectives
The aim was to evaluate the clinical, ultrasound (US) and, when indicated, the cytological and histological characteristics of autonomously functioning thyroid nodules (AFTN) in consecutive patients.
Methods
A prospective, single-centre study was conducted between March 2018 and September 2021. In total, 901 consecutive patients were referred for thyroid workup and of 67 AFTN were evaluated. All enrolled patients underwent 99mTcO4 − scintigraphy, additional 123I scintigraphy only in case of normal serum TSH, evaluation of thyroid function, US examination using European Thyroid Imaging and Reporting Data System (EU-TIRADS), and US-guided fine needle aspiration (FNA) cytology when indicated. All indeterminate FNA samples were subjected to DNA sequencing analysis.
Results
More than half of the evaluated patients with AFTN were euthyroid; median serum TSH was 0.41 (IQR: 0.03–0.97) mU/L. The median AFTN size measured by US was 27.0 (IQR: 21.1–35.0) mm. 28.4% of AFTN were classified as EU-TIRADS score 3 and 71.6% as EU-TIRADS score 4, indicating that the majority of AFTN had intermediate risk for malignancy according to US. Out of the 47 AFTN subjected to cytological evaluation, 24 (51%) yielded indeterminate FNA results. DNA sequencing revealed pathogenic TSHR and GNAS mutations in 60% of cases. No malignancy was detected at final histology in surgically excised AFTN (n = 12).
Conclusions
Of the 67 AFTN evaluated in this study, 50% presented with normal serum TSH, 70% displayed ultrasound features suggesting an intermediate malignancy risk and 50% of the AFTN submitted to cytology yielded indeterminate results. No malignant AFTN was detected.
Search for other papers by Lise Husted in
Google Scholar
PubMed
Search for other papers by Sidsel Rødgaard-Hansen in
Google Scholar
PubMed
Search for other papers by Maja Hjelm Lundgaard in
Google Scholar
PubMed
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Search for other papers by Nanna Maria Uldall Torp in
Google Scholar
PubMed
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Search for other papers by Stine Linding Andersen in
Google Scholar
PubMed
Objective
The physiological adaptations during a normal pregnancy affect renal and thyroid function and levels of associated biochemical markers. An association between cystatin C (CysC), creatinine, and thyroid function has been considered in nonpregnant individuals but not in pregnant women specifically.
Methods
Cohort study within the North Denmark Region Pregnancy Cohort (2011–2015) with assessment of thyroid function and autoantibodies (ADVIA Centaur XPT, Siemens Healthineers) in serum residues from the early pregnancy. Consecutive samples (n = 1112) were selected for measurement of CysC and creatinine (Atellica CH 930, Siemens Healthineers), and results were linked to information in Danish nationwide registers for (i) establishment of pregnancy-specific reference intervals for CysC and creatinine and (ii) evaluation of the prevalence of maternal hypothyroidism in early pregnancy according to levels of CysC and creatinine.
Results
The established reference intervals (2.5–97.5 percentiles) differed by week of pregnancy (week 4–8, 9–11, 12–15) and were CysC: 0.58–0.92 mg/L; 0.54–0.91 mg/L; 0.52–0.86 mg/L; creatinine: 46.9–73.0 µmol/L; 42.0–68.4 µmol/L; 38.8–66.4 µmol/L. The prevalence of maternal autoimmune hypothyroidism in early pregnancy differed by the level of CysC and creatinine (<25th percentile; 25th–75th percentile; >75th percentile) and was for CysC 1.7%, 3.8%, 7.4% and for creatinine 2.5%, 4.1%, 7.1%.
Conclusions
Reference intervals for CysC and creatinine were dynamic in early pregnancy and decreased with increasing gestational age. Furthermore, higher levels of CysC and creatinine associated with a higher prevalence of maternal autoimmune hypothyroidism. Results encourage considerations on the underlying mechanisms for the association between markers of renal and thyroid function.
Search for other papers by Hai-Yan Jia in
Google Scholar
PubMed
Search for other papers by Juan Chen in
Google Scholar
PubMed
Search for other papers by Zi-Xin Zhai in
Google Scholar
PubMed
Search for other papers by Wen-Wen Fan in
Google Scholar
PubMed
Search for other papers by Si-Jie Yuan in
Google Scholar
PubMed
Search for other papers by Qiong Liu in
Google Scholar
PubMed
Search for other papers by Xiao-Hui Yan in
Google Scholar
PubMed
Search for other papers by Qian-Qian Shen in
Google Scholar
PubMed
Search for other papers by Li-Ping Liu in
Google Scholar
PubMed
Introduction
Thyroid metastasis from clear cell renal cell carcinoma (ccRCC) is relatively rare, so ultrasound doctors lack experience with the disease, which can easily lead to misdiagnosis. We describe three cases of thyroid metastasis from ccRCC detected 12, 8, and 7 years after nephrectomy.
Case presentation
The first patient, a 78-year-old woman, was admitted to our institution for hoarseness and progressive dyspnea. Ultrasonography revealed bilateral thyroid nodules and abnormal cervical lymph nodes. Fine-needle aspiration biopsy (FNAB) and core needle biopsy (CNB) of the thyroid was nondiagnostic. The other two patients, a 54-year-old man and a 65-year-old man, were admitted to our institution for a goiter pressing on the trachea. In each case, ultrasonography revealed a partially cystic nodule of the left lobe of the thyroid gland. Histological examination of three patients after thyroidectomy showed thyroid metastasis from ccRCC.
Discussion/Conclusion
For patients with a history of ccRCC, long-term follow-up and routine thyroid ultrasonography should be performed. If a new thyroid nodule is found during the examination, metastases should be highly suspected. FNAB should be performed, even if benign ultrasound features seem to be in evidence. If the diagnosis of FNAB is incorrect and inconclusive, CNB should be performed.
Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University Sejong Hospital, Sejong, Republic of Korea
Search for other papers by Ho-Ryun Won in
Google Scholar
PubMed
Search for other papers by Min Gyu Kim in
Google Scholar
PubMed
Search for other papers by Min Soo Kim in
Google Scholar
PubMed
Department of Otolaryngology-Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
Search for other papers by Jae Won Chang in
Google Scholar
PubMed
Department of Otolaryngology-Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
Search for other papers by Bon Seok Koo in
Google Scholar
PubMed
Objective
Active surveillance (AS) has been suggested as a management option for low-risk papillary thyroid microcarcinoma (PTMC). However, the currently proposed selection criteria for AS application do not consider various clinical factors. The purpose of this study was to analyze clinical factors related to recurrence that could be confirmed preoperatively in patients who underwent surgery for PTMC and to identify factors worth considering when deciding whether to apply AS.
Materials and methods
Data were collected from patients with PTMC who underwent surgical treatment at Chungnam National University Hospital. A retrospective cohort was established according to the presence or absence of recurrence during the follow-up period. In total, 2717 patients were enrolled, of whom 60 experienced recurrence. Various clinical factors that could be identified before surgery were analyzed.
Results
The relationship between various clinical factors that could be confirmed preoperatively and recurrence was confirmed through Cox regression analysis and Kaplan–Meier curve analysis. BRAF mutation and the tall cell variant were significantly more common in patients with recurrence. In patients aged 55 years or older, the risk of recurrence was lower than in younger patients, while the recurrence-free survival (RFS) rate was higher.
Conclusion
When choosing between surgical treatment or AS in PTMC patients, additional consideration of the patient’s clinical factors, such as age and BRAF mutation status, may be required in addition to the existing criteria.
Search for other papers by Sander Barnhoorn in
Google Scholar
PubMed
Search for other papers by Marcel E Meima in
Google Scholar
PubMed
Search for other papers by Robin P Peeters in
Google Scholar
PubMed
Search for other papers by Veerle M Darras in
Google Scholar
PubMed
Search for other papers by Selmar Leeuwenburgh in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Oncode Institute, Utrecht, The Netherlands
Institute for Genome Stability in Ageing and Disease, CECAD Research Centre, Cologne, Germany
Search for other papers by Jan H J Hoeijmakers in
Google Scholar
PubMed
Oncode Institute, Utrecht, The Netherlands
Search for other papers by Wilbert P Vermeij in
Google Scholar
PubMed
Search for other papers by W Edward Visser in
Google Scholar
PubMed
Background
Thyroid hormone signaling is essential for development, metabolism, and response to stress but declines during aging, the cause of which is unknown. DNA damage accumulating with time is a main cause of aging, driving many age-related diseases. Previous studies in normal and premature aging mice, due to defective DNA repair, indicated reduced hepatic thyroid hormone signaling accompanied by decreased type 1 deiodinase (DIO1) and increased DIO3 activities. We investigated whether aging-related changes in deiodinase activity are driven by systemic signals or represent cell- or organ-autonomous changes.
Methods
We quantified liver and plasma thyroid hormone concentrations, deiodinase activities and expression of T3-responsive genes in mice with a global, liver-specific and for comparison brain-specific inactivation of Xpg, one of the endonucleases critically involved in multiple DNA repair pathways.
Results
Both in global and liver-specific Xpg knockout mice, hepatic DIO1 activity was decreased. Interestingly, hepatic DIO3 activity was increased in global, but not in liver-specific Xpg mutants. Selective Xpg deficiency and premature aging in the brain did not affect liver or systemic thyroid signaling. Concomitant with DIO1 inhibition, Xpg −/− and Alb-Xpg mice displayed reduced thyroid hormone-related gene expression changes, correlating with markers of liver damage and cellular senescence.
Conclusions
Our findings suggest that DIO1 activity during aging is predominantly modified in a tissue-autonomous manner driven by organ/cell-intrinsic accumulating DNA damage. The increase in hepatic DIO3 activity during aging largely depends on systemic signals, possibly reflecting the presence of circulating cells rather than activity in hepatocytes.
